| Mrs Summer Dawn Feaster, LICSW | |
|
9040 Reid Street, Attn: Mchj-clq-q, Tacoma, AA 98431-1100 | |
| (253) 968-2252 | |
| (253) 968-3278 |
| Full Name | Mrs Summer Dawn Feaster |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 9040 Reid Street, Tacoma, Armed Forces Americas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467939959 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | LW60807313 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Summer Dawn Feaster, LICSW 20021 96th Avenue Ct E, Graham, WA 98338-8281 Ph: (206) 550-4860 | Mrs Summer Dawn Feaster, LICSW 9040 Reid Street, Attn: Mchj-clq-q, Tacoma, AA 98431-1100 Ph: (253) 968-2252 |
News Archive
Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's list of "100 Best Companies to Work For" 2010. This is the second consecutive year that Novo Nordisk has been recognized with this prestigious award. Novo Nordisk moved up to 25 from 57 in the overall list and is only one of two pharmaceutical/biotechnology companies so honored.
Studying brain scans and cerebrospinal fluid of healthy adults, scientists have shown that changes in key biomarkers of Alzheimer's disease during midlife may help identify those who will develop dementia years later, according to new research.
WiserTogether, Inc., a healthcare treatment comparison tool, has established a relationship with Best Doctors, Inc., the global health services company that brings together the best minds in medicine to help people get the right diagnosis and treatment plan.
In the first known study to examine the prevalence and treatment of psoriasis in older Americans, experts from the Perelman School of Medicine at the University of Pennsylvania have found that black patients receiving Medicare are less likely to receive biologic therapies -medications derived from human or animal cells or tissues - for the treatment of moderate to severe psoriasis than white patients.
Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners.
› Verified 8 days ago